Welcome to Coulter Partners Global (English)

23 October 2025

Coulter Partners places R&D Senior Project Director at Vicore Pharma Holding

Coulter Partners successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.

Vicore Pharma is a clinical-stage pharmaceutical company focused on developing treatments for severe respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company is developing a new class of drugs with disease-modifying potential.

Katrine Husum has more than 20 years of experience in the biopharmaceutical industry, specializing in project and alliance management. She has led drug development projects with global cross-functional teams and strategic partnerships across the R&D value chain. Her previous roles include Head of Project and Alliance Management at Nykode Therapeutics and various Project Director roles at Leo Pharma, Takeda and Nycomed.

Commenting on the appointment, Ahmed Mousa, Vicore Pharma’s Chief Executive Officer said: “Identifying the right talent is essential to advancing our mission. We appreciate Coulter Partners’ partnership in understanding our needs and helping us secure a candidate whose expertise will strengthen our ability to deliver meaningful therapies for patients.”

----

Katrine Husum, R&D Senior Project Director at Vicore Pharma

Katrine Husum, R&D Senior Project Director at Vicore Pharma

About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). 

For more information: www.vicorepharma.com
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Related

A new version of Coulter Partners is available.